WGS Profile
GeneDx Holdings Corp., operating under the name GeneDx, is a leading health information and genomic analysis company focused on transforming the diagnosis, treatment, and prevention of diseases through advanced data-driven approaches. The company's flagship platform, Centrellis, leverages artificial intelligence to provide deep, actionable insights for biopharmaceutical companies. This platform accelerates the drug discovery, development, and commercialization processes by offering extensive analytics, pre-clinical and clinical trial support, and high-resolution genomic sequencing services.
GeneDx's portfolio includes Sema4 Signal, an innovative tool that enhances precision oncology by integrating data across the continuum of cancer care, from prevention and early detection to treatment and remission. This platform supports oncologists with tailored treatment options and helps in monitoring patient outcomes. Additionally, GeneDx provides a comprehensive range of genetic testing services, including carrier screening, non-invasive prenatal testing, newborn screening, and hereditary cancer testing, catering to diverse genetic and prenatal diagnostic needs.
The company also plays a crucial role in public health through its COVID-19 testing solutions, which support ongoing efforts to manage and mitigate the impact of the pandemic. GeneDx's testing services are designed to deliver accurate and timely results, contributing to the broader public health response.
Founded in 2020 and headquartered in Stamford, Connecticut, GeneDx Holdings Corp. is at the forefront of integrating genomic and health data to drive medical innovations. Its commitment to advancing healthcare through cutting-edge technologies and comprehensive data solutions positions it as a pivotal player in the evolving landscape of personalized medicine and genomic diagnostics.
|
